Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

NCT04378543 is registered in ClinicalTrials.gov with Ankasa Regenerative Therapeutics, Inc. as lead sponsor.

NCT NCT04378543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04378543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion
Lead sponsor
Ankasa Regenerative Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2020
Completion date
October 31, 2023
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative spondylolisthesis